
AgelessRx Launches GHK-Cu Cream for Age-Related Skin Repair
Edited by Vita Solenne
Research & Biotech · Updated October 9, 2026
AgelessRx has introduced GHK-Cu Cream, a prescription copper peptide cream aimed at aiding tissue repair and renewal that diminishes with age. The cream is available in clinician-guided concentrations of 0.5% and 3%, allowing healthcare providers to tailor treatments based on individual patient needs. This product represents a new option for those seeking to address age-related skin changes.
Share this story
Why it matters
- ✓GHK-Cu is known for its potential to enhance skin repair and rejuvenation, which may appeal to individuals focused on maintaining youthful skin as they age.
- ✓The ability to customize treatment concentrations allows for personalized approaches to skin health, aligning with the principles of health optimization.
- ✓As a prescription product, GHK-Cu Cream may provide a more effective alternative to over-the-counter anti-aging products.
AgelessRx Launches GHK-Cu Cream for Age-Related Skin Repair
AgelessRx has recently unveiled its new product, GHK-Cu Cream, a topical formulation that aims to support skin repair and renewal processes that typically decline with age. This innovative cream leverages the properties of copper peptides, specifically GHK-Cu, which have been studied for their potential benefits in skin health and regeneration.
What is GHK-Cu?
GHK-Cu, or Glycyl-L-Histidyl-L-Lysine Copper, is a naturally occurring peptide that has garnered attention in the field of dermatology and longevity science. It is known for its ability to promote wound healing, stimulate collagen production, and enhance tissue repair. As skin ages, its natural regenerative abilities diminish, leading to wrinkles, sagging, and other signs of aging. GHK-Cu Cream aims to counteract these effects by providing a topical source of this beneficial peptide.
Product Details
AgelessRx offers GHK-Cu Cream in two clinician-guided concentrations: 0.5% and 3%. This allows healthcare providers to select the appropriate strength based on various factors, including the patient's medical history, the specific area being treated, and the individual's tolerance to the formulation. This customization is particularly significant in the realm of health optimization, as it aligns with the growing trend of personalized medicine.
Implications for Skin Health
The introduction of GHK-Cu Cream could have several implications for those interested in longevity and skin health:
-
Enhanced Skin Repair: By utilizing GHK-Cu, the cream may help improve skin elasticity and reduce the appearance of fine lines and wrinkles, making it a valuable tool for those looking to maintain youthful skin.
-
Personalized Treatment Options: The availability of different concentrations allows for tailored treatment plans, which can lead to better outcomes and increased patient satisfaction.
-
Prescription-Only Access: As a prescription product, GHK-Cu Cream may offer a more potent alternative to over-the-counter anti-aging products, potentially leading to more significant and noticeable results.
Conclusion
The launch of GHK-Cu Cream by AgelessRx represents a noteworthy advancement in the field of age-related skin repair. By harnessing the power of copper peptides, this product aims to support skin rejuvenation in a scientifically backed manner. For individuals pursuing longevity and health optimization, GHK-Cu Cream may provide a promising option to enhance skin health and combat the visible effects of aging. As more research emerges on the efficacy and safety of GHK-Cu in topical applications, it will be interesting to see how it fits into the broader landscape of anti-aging treatments and longevity strategies.
Sources
- AgelessRx introduces GHK-Cu Cream for age-related skin repair — Longevity Technology
Newsletter
Your weekly longevity signal. No spam.
Comments
Log in with
Loading comments…
More in Biotech

Exploring the Connection Between Big Pharma and Gray-Market Peptides
A recent analysis reveals significant ties between the pharmaceutical industry and gray-market…
1d ago

Kailera Completes Enrollment for Obesity Trials, Results Expected in 2028
Kailera has completed enrollment for its three Phase 3 trials of ribupatide, a weekly injection…
2d ago

Longeveron’s Stem Cell Therapy Shows Promise for Reducing Brain Inflammation in Alzheimer’s Patients
Longeveron has released new preclinical data suggesting that its stem cell therapy may lead to…
2d ago

Heart Pill Reduces Inflammation Markers in Initial Study
Monte Rosa's NEK7-targeting drug has shown promise in reducing several heart-risk biomarkers in a…
2d ago